Heartflow, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a company in a high-stakes transition from a venture-backed startup to a public AI healthcare leader. The fundamental tension lies between impressive top-line momentum and a persistent inability to reach profitability. While the 80% gross margin suggests a highly scalable software model, the ballooning SG&A and R&D expenses indicate that the cost of acquiring and maintaining that growth remains steep. Investors are now weighing the strength of a clean, debt-free balance sheet against the uncertainty of a DOJ investigation and the risk of single-product dependency. The upcoming results of randomized clinical trials and the adoption rate of Plaque Analysis will be the primary determinants of whether Heartflow can convert its technical lead into a sustainable, profitable business model.